Hyloris Pharmaceuticals is an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals.
Hyloris adds value to healthcare systems by enhancing the potential of well-known pharmaceuticals.
Hyloris was founded in 2013 by Stijn Van Rompay and Thomas Jacobsen. The company is headquartered in Liège, Liège, Belgium.
Hyloris Pharmaceuticals unlocks the untapped potentials of existing medications to create new and improved treatment options.
Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system.
Hyloris’ portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialised through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain.
Hyloris Pharmaceuticals has raised €15M in a new round of funding on April 30, 2020. Backers included Scorpiaux, Noshaq, Saffelberg Investments and Nomainvest.